Monopar Therapeutics (MNPR) Debt Ratio (2020)

Monopar Therapeutics (MNPR) reported Debt Ratio of 0.01 for Q3 2020, down 29.49% sequentially from 0.01 in Q2 2020.

Monopar Therapeutics (MNPR) Debt Ratio (2020) Analysis & Trends

Monopar Therapeutics (MNPR) has 1 years of Debt Ratio data on file, last reported at 0.01 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 1.41
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 0.11
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 0.05
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Monopar Therapeutics 800.03 Mn 738.20 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2020 0.01
Jun 30, 2020 0.01